Some Inconvenient Facts About Yervoy, Bristol-Myers' New "Holy Grail" Cancer Drug
Posted on March 28, 2011 at 12:32 PM EDT
BMS paid $2.1 billion to acquire a drug that may have cost less than $400 million to develop.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here